Filter‐based isolation, enrichment, and characterization of circulating tumor cells

Khetani, Sultan; Mohammadi, Mehdi; Nezhad, Amir Sanati

doi:10.1002/bit.26787

Cited by 59 publications

(36 citation statements)

References 185 publications

(416 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other methods of CTC isolation are label-free techniques utilizing filtration and fluid dynamics based on tumor cells size and deformability and not on epithelial marker detection. Different CTC collection and isolation techniques have been extensively reviewed, and thus will not be discussed here (reviewed in [48][49][50][51][52][53][54]). However, it is important to recognize that all studies discussed in this review did not use the same CTC isolation method and any incompatible results may be attributed to different CTC isolation approaches, and a component of variability is likely due to differences in detection method.…”

Section: Mechanisms For Tumor Cells To Enter the Vasculaturementioning

confidence: 99%

Gauging the Impact of Cancer Treatment Modalities on Circulating Tumor Cells (CTCs)

Mathias

Chang

Martin

et al. 2020

Cancers

View full text Add to dashboard Cite

The metastatic cascade consists of multiple complex steps, but the belief that it is a linear process is diminishing. In order to metastasize, cells must enter the blood vessels or body cavities (depending on the cancer type) via active or passive mechanisms. Once in the bloodstream and/or lymphatics, these cancer cells are now termed circulating tumor cells (CTCs). CTC numbers as well as CTC clusters have been used as a prognostic marker with higher numbers of CTCs and/or CTC clusters correlating with an unfavorable prognosis. However, we have very limited knowledge about CTC biology, including which of these cells are ultimately responsible for overt metastatic growth, but due to the fact that higher numbers of CTCs correlate with a worse prognosis; it would seem appropriate to either limit CTCs and/or their dissemination. Here, we will discuss the different cancer treatments which may inadvertently promote the mobilization of CTCs and potential CTC therapies to decrease metastasis.

show abstract

Section: Mechanisms For Tumor Cells To Enter the Vasculaturementioning

confidence: 99%

Gauging the Impact of Cancer Treatment Modalities on Circulating Tumor Cells (CTCs)

Mathias

Chang

Martin

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…3(B). In brief, microfluidic enrichment systems have been developed making use of acoustophoresis, 192 electrophoresis, 186 dielectrophoresis, 193 magnetophoresis, 194 or optical forces, 195 as well as passive systems that use inertial effects, 196 filters, 197 or immobilization processes. 198 While demonstrating significant potential, many of the separation systems explored in the literature are in the prototype or proof-of-concept stage, 189 with few demonstrating the performance required for fully integrated systems.…”

Section: Cell Enrichment Strategiesmentioning

confidence: 99%

A Review of Design Considerations for Hemocompatibility within Microfluidic Systems

Szydzik

Brazilek

Nesbitt

2020

Semin Thromb Hemost

View full text Add to dashboard Cite

The manipulation of blood within in vitro environments presents a persistent challenge, due to the highly reactive nature of blood, and its multifaceted response to material contact, changes in environmental conditions, and stimulation during handling. Microfluidic Lab-on-Chip systems offer the promise of robust point-of-care diagnostic tools and sophisticated research platforms. The capacity for precise control of environmental and experimental conditions afforded by microfluidic technologies presents unique opportunities that are particularly relevant to research and clinical applications requiring the controlled manipulation of blood. A critical bottleneck impeding the translation of existing Lab-on-Chip technology from laboratory bench to the clinic is the ability to reliably handle relatively small blood samples without negatively impacting blood composition or function. This review explores design considerations critical to the development of microfluidic systems intended for use with whole blood from an engineering perspective. Material hemocompatibility is briefly explored, encompassing common microfluidic device materials, as well as surface modification strategies intended to improve hemocompatibility. Operational hemocompatibility, including shear-induced effects, temperature dependence, and gas interactions are explored, microfluidic sample preparation methodologies are introduced, as well as current techniques for on-chip manipulation of the whole blood. Finally, methods of assessing hemocompatibility are briefly introduced, with an emphasis on primary hemostasis and platelet function.

show abstract

“…The cytological characteristics of CTCs have led to the development of microfiltration devices in order to capture these rare cell events [23,26]. Microfiltration is a simple process allowing the enrichment of large volumes of blood in minutes with a high recovery rate (>85 % depending on the device used) and is independent of any biomarkers expressed by CTCs.…”

Section: Isolation By Microfiltrationmentioning

confidence: 99%

Characterization of circulating tumor cells as a reflection of the tumor heterogeneity: myth or reality?

Brown

Gabriel

Cartron

et al. 2019

Drug Discovery Today

View full text Add to dashboard Cite

Oncology has entered in the era of personalized medicine with its advantages such as limited invasiveness during sample collection, robustness, precision and speed. This new era has led to novel practices of tissue sampling (e.g. needle biopsy) and the main goal of diagnostic medicine is now to detect crucial events in "infinitely" small samples. The key question is now to determine if the rare cell events isolated and characterized from these samples are reliably reflecting the initial and/or metastatic disease and particularly the heterogeneity of the tumor. The present review will give a short overview of the most recent methods developed for the isolation and characterization of rare cell events in clinical practice with a specific focus on circulating tumor cells. We will discuss the biological value to study these cells at the single cell level and how these rare cell events can reflect tumor heterogeneity. The potential biomedical applications (disease modeling, drug screening, therapeutic decision, monitoring, etc.) will be critically discussed in light of precision medicine.

show abstract

Filter‐based isolation, enrichment, and characterization of circulating tumor cells

Cited by 59 publications

References 185 publications

Gauging the Impact of Cancer Treatment Modalities on Circulating Tumor Cells (CTCs)

Gauging the Impact of Cancer Treatment Modalities on Circulating Tumor Cells (CTCs)

A Review of Design Considerations for Hemocompatibility within Microfluidic Systems

Characterization of circulating tumor cells as a reflection of the tumor heterogeneity: myth or reality?

Contact Info

Product

Resources

About